

Clinical Isolates Resistance to Commonly Used Antibiotics: A Concern in Healthcare Setting

Olise CC^{1*}, Simon-Oke IA¹ and Akumeh DD²

¹Department of Biology, Environmental and Public Health Unit, Federal University of Technology, Akure, Nigeria

²Department of Microbiology, Federal University of Technology, Akure, Nigeria

Abstract

Antibiotics resistance is a global issue, becoming more intensified because of the diminishing number of new antibiotics. Samples were collected aseptically from hospital surfaces with swab sticks. Isolated microorganisms from the samples collected were identified using standard microbiological methods. A total of 109 isolates were obtained *Staphylococcus aureus* (29), *Staphylococcus epidermidis* (13), *Streptococcus spp.* (16), *Escherichia coli* (8), *Klebsiella pneumonia* (7), *Proteus spp* (5), *Enterobacter aerogenes* (6), *Bacillus cereus* (10), *Micrococcus leteus* (6) and *Pseudomonas aeruginosa* (9). Gram negative bacterial isolated in the study shows multi-drug resistance to about four to five of the antibiotics tested. Most notably *E. coli*, *Enterobacter aerogenes*, *Klebsiella pneumonia*, and *Proteus mirabilis*. Although Tarivid and Perfloracin demonstrated a high potency against these organisms. All Gram positive isolate shows 100% resistance to Ampiclox and Zannicef. *Staphylococcus epidermidis*, and *Staphylococcus aureus* shows resistance to multiple antibiotics. The present of multidrug resistance microorganism in hospital environment is a concern in healthcare delivery.

Keywords: Antibiotics resistance; Antibiotics; Healthcare; Microorganism

Introduction

Hospitals environments provide anchorage for multi-drug resistant microorganisms borne by patients and staff. Antimicrobial resistance in diseases causing microorganisms is a well-known problem hampering quality healthcare delivery worldwide [1,2]. Antibiotics resistance is a global issue, becoming more intensified because of the diminishing number of new antibiotics produced [3]. The potency of currently available antibiotics is decreasing due to the increasing number of resistant strains causing infections and evolving of new disease causing pathogens [4]. Antimicrobial-resistant bacteria is threatening the ability to effectively treat patients, emphasizing the need for continued surveillance, more appropriate antimicrobial prescription, prudent infection control, and new treatment alternatives [5-7].

Material and Methods

Study site

Male surgical ward, Female surgical, Intensive care unit, Accident and Emergency ward, and Children ward of the State Specialist Hospital, Akure, Ondo State, Nigeria.

Ethical consideration

A letter of ethical consideration was collected from the Chief Medical Director who is the chairman of the ethical committee of the hospital, for sample collections

Surface sampled

Bed rail, Bed linen, Pillow case, Fan switch, Drip stand, Door knob, Chair, Sink knob, and Light-plug-ins.

Swab samples

Using swab sticks soaked in 8.5% physiological saline samples were taking by rubbing the surfaces with swab sticks. The samples were packed in airtight test tubes and taking to the laboratory for microbial analysis.

Isolation and identification of bacteria

Swab sticks were streaked on already prepared culture media in Petri dishes, the Petri dishes were then incubated for 24 hours, and isolated bacteria were identified through morphological and biochemical tests.

Antibiotic susceptibility test of Gram positive and Gram negative bacteria isolates

The Kirby-Bauer Disc Diffusion Method according to the method of (CLSI, 2003) was used to test the susceptibility of the identified Gram positive bacteria isolates to Septrin (SXT, 30 µg), Erythromycin (E, 10 µg), Pefloxacin (PEF, 30 µg), Gentamycin (GEN, 30 µg), Ampiclox (APX, 30 µg), Zinnacef (Z, 30 µg), Amoxacillin (Am, 30 µg), Rocephin (R, 25 µg), Ciprofloxacin (CPX, 10 µg), Streptomycin (S, 30 µg), while Gram negative bacteria were tested to Gentamicin (CN) 10 µg, Septrin (SXT) 30 µg, Chloramphenicol (CH) 30 µg, Ciprofloxacin (CPX) 10 µg, Amoxacillin (AM) 30 µg, Augmentin (AU) 30 µg, Pefloxacin (PEF) 30 µg, Tarivid (OFX) 10 µg, Streptomycin (S) 30 µg and Sparfloxacin (SP) 10 µg. A sterile platinum loop was used to pick colonies of isolates from the culture plate and emulsified into 4 ml of sterile peptone water to match with 0.5 McFarland turbidity standards (10⁵ CfU/ml). Using a sterile swab, the surface of Mueller Hinton Agar (Oxoid, Basingstoke, UK) in a Petri dish was evenly inoculated with the suspension of the isolates. With the Petri dish lid in place, about 10 minutes was allowed for the surface of the agar to dry. A multichannel disc dispenser (Oxoid, Basingstoke, UK) was used to deposit the antibiotics discs onto the surface of the inoculated medium. The plate was then incubated at

***Corresponding author:** Olise Christian Chukwu, Department of Biology, Environmental and Public Health Unit, Federal University of Technology, Akure, Nigeria, Tel: +2348102813026; E-mail: olisechristian84@yahoo.com

Received March 12, 2018; **Accepted** March 21, 2018; **Published** March 26, 2018

Citation: Olise CC, Simon-Oke IA, Akumeh DD (2018) Clinical Isolates Resistance to Commonly Used Antibiotics: A Concern in Healthcare Setting. Int J Pub Health Safe 3: 150.

Copyright: © 2018 Olise CC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

37°C for 18 hours each isolate tested was replicated in triplicate. The diameters of the zones of inhibition were measured in millimeters. The diameter of the zone of clearance (including the diameter of the disk) was measured to the nearest whole millimeter and interpreted on the basis of CLSI guideline (CLSI, 2005).

Results

Isolated bacteria

The morphological and biochemical characteristics of the isolated bacteria. *Escherichia coli*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Proteus mirabilis* and *Enterobacter aerogenes* are all Gram negative bacteria and rod-like in nature. *Escherichia coli* and *Klebsiella pneumoniae* are indole positive. *Proteus mirabilis* and *Klebsiella pneumoniae* are urease positive. All Gram negative isolates are catalase positive but coagulase negative except *Pseudomonas aeruginosa*. *Proteus mirabilis* is the only spore forming and citrate positive Gram negative isolate, while they are positive to motility test. *Escherichia coli* and *Enterobacter aerogenes* are positive to all the sugar tests. All the Gram positive isolates are cocci in shape except *Bacillus cereus*. *Staphylococcus aureus* and *S. epidermidis* have a cluster arrangement. *Staphylococcus aureus* is the only Gram positive isolate that fermented all the sugar used. They are all indole negative except *Bacillus cereus*. *Staphylococcus aureus*, *S. pneumoniae* and *M. luteus* urease positive, while *S. faecalis* and *S. pneumoniae* are catalase negative. Coagulase positive isolates are *Bacillus cereus* and *Staphylococcus aureus*, while *S. pneumoniae* is citrate negative (Table 1).

aureus and *S. epidermidis* have a cluster arrangement. *Staphylococcus aureus* is the only Gram positive isolate that fermented all the sugar used. They are all indole negative except *Bacillus cereus*. *Staphylococcus aureus*, *S. pneumoniae* and *M. luteus* urease positive, while *S. faecalis* and *S. pneumoniae* are catalase negative. Coagulase positive isolates are *Bacillus cereus* and *Staphylococcus aureus*, while *S. pneumoniae* is citrate negative (Table 1).

Distribution of bacterial isolates across the wards

The distribution of bacterial isolates across the wards, *Staphylococcus aureus*, and *Escherichia coli* were predominant compared to other isolates which were less predominant. Analysis shows that distribution of bacteria species across the sampled wards is significantly different at (P=0.00) (Figure 1).

Antibiotic susceptibility pattern of Gram positive bacterial isolates

The antibiotic susceptibility pattern of Gram negative bacteria isolate in relation to inhibition zone. *Enterobacter aerogenes* shows multi

| Shape | Arrange-ment | Gram stain-ing | Indole test | Urease test | Cata-lase | Coagu-lase | Oxi-dase | Spore staining | Citrate | Motility | Sugar fermentation test | | | | | Probable isolates |
|-----------|--------------|----------------|-------------|-------------|-----------|------------|----------|----------------|---------|----------|-------------------------|---------|---------|----------|-----------------------|-------------------|
| | | | | | | | | | | | Lactose | Sucrose | Glucose | Mannitol | Maltose | |
| Short Rod | singly | - | + | - | + | - | - | - | - | + | + | + | + | + | <i>E. coli rod</i> | |
| Short Rod | singly | - | + | + | + | - | - | - | + | + | + | - | + | - | <i>K. pneumoniae</i> | |
| Small Rod | singly | - | - | - | + | - | + | - | + | + | - | - | - | + | <i>P. aeruginosa</i> | |
| Cocci | cluster | + | - | + | + | + | - | - | + | - | + | + | + | + | <i>S. aureus</i> | |
| Cocci | singly | + | - | - | - | - | NT | NT | - | + | + | + | + | + | <i>S. pneumoniae</i> | |
| Long Rod | singly | + | + | - | + | + | - | + | + | + | - | + | + | NT | <i>B. cereus</i> | |
| Rod | singly | - | - | + | + | - | - | + | + | + | - | + | + | - | <i>P. mirabilis</i> | |
| Cocci | cluster | + | - | + | + | - | - | - | + | - | + | + | + | - | <i>S. epidermidis</i> | |
| Cocci | singly | + | - | - | - | - | - | - | - | - | - | - | - | - | <i>S. faecalis</i> | |
| Cocci | cluster | + | - | + | + | - | + | - | + | + | + | + | - | + | <i>M. luteus</i> | |
| Rod | singly | - | - | - | + | NT | - | - | + | + | + | + | + | + | <i>E. aerogenes</i> | |

NT=Not tested; (+)=Positive; (-)=Negative

Table 1: Identification of bacteria isolates.




Figure 1: Distribution of bacterial isolates across the wards (X²=0.00, P<0.05).

| Antibiotic | <i>Proteus mirabilis</i> | <i>Enterobacter aerogenes</i> | <i>Pseudomonas aeruginosa</i> | <i>Escherichia coli</i> | <i>Klebsiella pneumonia</i> |
|-----------------|---------------------------|-------------------------------|-------------------------------|---------------------------|-----------------------------|
| AMOXACILIN | 0.00 ± 0.00 ^a | 0.00 ± 0.00 ^a | 2.20 ± 0.37 ^b | 0.00 ± 0.00 ^a | 3.80 ± 0.86 ^b |
| PEFLOXACIN | 9.10 ± 0.81 ^{bc} | 0.00 ± 0.00 ^a | 11.50 ± 1.67 ^c | 6.40 ± 1.03 ^b | 11.00 ± 1.18 ^{bc} |
| TARIVID | 4.14 ± 1.04 ^{ab} | 0.00 ± 0.00 ^a | 11.60 ± 1.57 ^c | 7.20 ± 1.59 ^{bc} | 8.90 ± 0.87 ^{bc} |
| STREPTOMICIN | 0.00 ± 0.00 ^a | 0.00 ± 0.00 ^a | 0.00 ± 0.00 ^a | 2.70 ± 0.66 ^b | 0.00 ± 0.00 ^a |
| CHLORAMPHENICOL | 0.00 ± 0.00 ^a | 0.00 ± 0.00 ^a | 0.00 ± 0.00 ^a | 0.00 ± 0.00 ^a | 0.00 ± 0.00 ^a |
| CIPROFLOXACIN | 9.60 ± 0.5 ^d | 1.90 ± 0.25 ^b | 5.44 ± 0.73 ^c | 1.70 ± 0.37 ^{ab} | 0.00 ± 0.00 ^a |
| AUGUMENTIN | 0.00 ± 0.00 ^a | 0.00 ± 0.00 ^a | 0.10 ± 0.10 ^b | 0.00 ± 0.00 ^a | 0.00 ± 0.00 ^a |
| GENTAMICIN | 1.50 ± 0.22 ^a | 0.50 ± 0.32 ^a | 0.00 ± 0.00 ^a | 0.00 ± 0.00 ^a | 1.50 ± 0.22 ^a |
| SEPTRIN | 0.00 ± 0.00 ^a | 2.20 ± 0.37 ^a | 1.20 ± 0.20 ^a | 1.30 ± 0.20 ^a | 8.60 ± 1.96 ^b |
| SPARFLOXACIN | 5.50 ± 0.86 ^b | 0.00 ± 0.00 ^a | 3.80 ± 0.68 ^{bc} | 0.00 ± 0.00 ^a | 1.90 ± 0.40 ^{ab} |

A result of the mean of five replicates ± standard error. Values with different superscript within the same column are significantly different at p<0.05 using Tukey.

Table 2: Zone of inhibition in mm of Gram positive bacteria isolates to antibiotics.

| Antibiotic | <i>S. aureus</i> | <i>S. pneumonia</i> | <i>B. cereus</i> | <i>S. faecalis</i> | <i>M. luteus</i> | <i>S. epidermidis</i> |
|---------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
| AMOXACILIN | 0.00 ± 0.00 ^a | 4.60 ± 0.51 ^b | 4.00 ± 0.71 ^b | 0.00 ± 0.00 ^a | 0.00 ± 0.00 ^a | 0.00 ± 0.00 ^a |
| ROCEPHIN | 3.80 ± 0.58 ^{bc} | 5.00 ± 0.32 ^c | 0.00 ± 0.00 ^a | 4.40 ± 0.40 ^c | 2.70 ± 0.37 ^b | 0.00 ± 0.00 ^a |
| CIPROFLOXACIN | 5.30 ± 0.64 ^b | 9.40 ± 0.51 ^c | 5.00 ± 0.71 ^b | 9.00 ± 0.89 ^{bc} | 17.40 ± 1.78 ^d | 0.00 ± 0.00 ^a |
| AMPICLOX | 0.00 ± 0.00 ^a |
| STREPTOMYCIN | 11.60 ± 0.92 ^d | 5.60 ± 0.51 ^c | 3.10 ± 0.51 ^b | 4.00 ± 0.32 ^{bc} | 3.60 ± 0.51 ^{bc} | 0.00 ± 0.00 ^a |
| ZANNICEF | 0.00 ± 0.00 ^a |
| SEPTRIN | 4.80 ± 0.60 ^{bc} | 0.00 ± 0.00 ^a | 0.10 ± 0.10 ^b | 0.00 ± 0.00 ^a | 3.60 ± 0.51 ^b | 0.00 ± 0.00 ^a |
| ERYTHROMYCIN | 6.40 ± 0.51 ^c | 0.00 ± 0.00 ^a | 4.40 ± 0.48 ^{bc} | 2.80 ± 0.37 ^b | 3.60 ± 0.51 ^b | 4.20 ± 0.37 ^b |
| PEFLOXACIN | 2.80 ± 0.37 ^a | 7.60 ± 0.51 ^c | 4.20 ± 0.37 ^{ab} | 5.40 ± 0.75 ^{bc} | 5.60 ± 0.68 ^{bc} | 11.60 ± 0.68 ^d |
| GENTAMYCIN | 0.00 ± 0.00 ^a | 11.40 ± 0.60 ^d | 2.80 ± 0.37 ^b | 0.00 ± 0.00 ^a | 8.80 ± 0.73 ^c | 0.00 ± 0.00 ^a |

A result of the mean of five replicates ± standard error. Values with different superscript within the same column are significantly different at p<0.05 using Tukey

Table 3: Zone of inhibition in mm of Gram negative bacteria isolates to antibiotics.

drug resistance against Amoxicilin, Pefloxacin, Tarivid, Stretomicin, and Chloramphenicol with no inhibition zone (0.00 ± 0.00), Klebsiella pneumonia also shows resistance to multiple antibiotics, Stretomicin, Chloramphenicol, Ciprofloxacin and Augumentin with no inhibition zone (0.00 ± 0.00). Pefloxacin is active against *Pseudomonas aeruginosa* (11.50 ± 1.67) and *E. aerogenes* (11.00 ± 1.18) while Tarivid has highest inhibitory zone against *Pseudomonas aeruginosa* (11.60 ± 1.57). *Proteus mirabilis* also shows resistance against, Chloramphenicol, Septrin, Augumentin, Streptomycin, and Amoxicilin with no zone of inhibition (0.00 ± 0.00). *E. coli* demonstrated multiple resistance has no zone of inhibition was recorded against Augumentin, Amoxicilin, Sparfloxacin and Gentamycin (Table 2).

Antibiotic susceptibility pattern of Gram negative bacterial isolates

The susceptibility pattern of Gram positive bacteria to antibiotics in relation to inhibition zone in millimetre. All Gram positive isolate shows resistance against Ampiclox and Zannicef with no zone of inhibition (0.00 ± 0.00). *Staphylococcus epidermidis* shows resistance to multiple antibiotics, Amoxicilin, Recophin, Ciprofloxacin, Ampiclox, Streptomycin, Zannicef, Septrin and Gentamycin with no zone of inhibition (0.00 ± 0.00). Ciprofloxacin is most active against *Micrococcus luteus* with a clear zone of 17.40 ± 1.78. Erythromycin shows potency against all Gram positive isolates except *S. pneumonia* while Pefloxacin shows potency against all Gram positive bacteria isolates. *Staphylococcus aureus* and *Streptococcus faecalis* shows were resistance Amoxicilin and Gentamycin (Table 3).

Discussion

The *in-vitro* antibiotic test reveal that most pathogens causing nosocomial infection are becoming more resistance to the commonly

use antibiotics. Most of the Gram negative isolated in the study shows multi-drug resistance to about four to five commonly used antibiotics. Most notably, *E. coli*, *Enterobacter aerogenes*, *Klebsiella pneumonia*, and *Proteus mirabilis* demonstrated multiple resistant to most of the antibiotics tested. Although Tarivid and Perfloxacin demonstrated a high potency, these might be due to the low prescription trends of it in the study area. The high rate of multiple resistance rate demonstrated by the Gram negative isolate may be due to the fact that these antibiotics having been in use for much longer time or over used and/or their oral route of administration might affected their rate of absorption into blood stream as explained [8]. Multi-drug resistance of Gram negative bacteria isolates have been reported by numerous studies [9]. Reported high rate of multiple drug resistance in *Enterobacteriaceae* isolated from hospital environments.

All Gram positive isolate shows 100% resistance to Ampiclox and Zannicef. *Staphylococcus epidermidis*, and *S. aureus* shows resistance to multiple antibiotics. *S. aureus* and *S. epidermidis* showed similar susceptibility pattern being highly susceptible to Streptomycin and resistant to Augmentin. Therefore Augmentin should not be recommended for the treatment of infections caused by these organisms [10]. Susceptibility of *S. aureus* and *S. epidermidis* in this study to Erythromycin does not necessary imply that these antibiotics may represent therapeutic options for infections caused by these organisms. The susceptibility of *Staphylococcus aureus* to erythromycin was in accordance with the report of who reported 41.86% rate of susceptibility of *Staphylococcus aureus* to erythromycin [11].

Conclusion

Although the study do not look into the resistant mechanism of these bacteria isolates using molecular typing, but it is evidence in this study that disease causing microorganisms are becoming resistance

to commonly used antibiotics. Antimicrobial surfaces should be introduced in our healthcare setting to help reduce microbial load on surfaces.

References

1. Oteo J, Campos J, Baquero F (2002) Antibiotic resistance in 1962 invasive isolates of *Escherichia coli* in 27 Spanish hospitals participating in the European antimicrobial resistance surveillance system. *J Antimicrob Chemother* 50: 945-952.
2. Okonko IO, Soley FA, Amusan TA, Ogun AA, Ogunnusi TA, et al. (2009) Incidence of Multi-Drug Resistance (MDR) organisms in Abeokuta, Southwestern Nigeria. *Global J Pharmacol* 3: 69-80.
3. Nkang AO, Okonko IO, Mejeha OK, Adewale OG, Udeze AO, et al. (2009) Assessment of antibiotics susceptibility profiles of some selected clinical isolates from laboratories in Nigeria. *J Microbiol Antimicrob* 1: 19-26.
4. Nawaz SK, Riaz S, Hasnain S (2009) Screening for anti-methicillin resistant *Staphylococcus aureus* (MRSA) bacteriocin producing bacteria. *Afr J Biotech* 8: 365-368.
5. Mulvey MR, Bryce E, Boyd D, Ofner-Agostini M, Christianson S, et al. (2004) Ambler class extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella* spp. in Canadian hospitals. *Antimicrob Agents Chemother* 48: 1204-1214.
6. Rhomberg PR, Fritsche TR, Sader HS, Jones RN (2006) Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from meropenem yearly susceptibility test information collection program (USA). *Diagn Microbiol Infect Dis* 56: 57-62.
7. Zhanel GG, DeCorby M, Laing N, Weshnowski B, Vashisht R, et al. (2008) Antimicrobial resistant pathogens in intensive care units in Canada: Results of the Canadian National Intensive Care Unit (CAN- ICU) study, 2005-2006. *Antimicrob Agents Chemother* 52: 1430-1437.
8. Anguzu JR, Olila D (2007) Drug sensitivity patterns of bacterial isolates from septic Postoperative wounds in a regional referral hospital in Uganda. *Afr Health Sci* 7: 148-154.
9. Wondemagegn M, Gebre K, Getenet B, Meku D (2012) Postoperative nosocomial infections and antimicrobial resistance pattern of bacteria isolates among patients admitted at Felege Hiwot referral hospital, Bahirdar, Ethiopia. *Ethiopian J Health Sci* 22: 7-18.
10. Aminu M, Usman-Sani H, Usman MA (2014) Characterization and determination of antibiotic susceptibility pattern of bacteria isolated from some fomites in a teaching hospital in northern Nigeria. *Afr J Microbiol Res* 8: 814-818.
11. Segujja F, Mwambi B, Drago CK, Lubowa MN, Mugambwa J, et al. (2016) Characterization and antimicrobial susceptibility of isolates from ward fomites. *British Biotechnol J* 14: 1-16.